2022
DOI: 10.1155/2022/5824183
|View full text |Cite
|
Sign up to set email alerts
|

A Systematic Review and Meta‐analysis on the Occurrence of Biomarker Mutation in Colorectal Cancer among the Asian Population

Abstract: Globally, colorectal carcinoma (CRC) is the third most common cancer and the third major cause of cancer-related death in both sexes. KRAS and BRAF mutations are almost mutually exclusively involved in the pathogenesis of CRC. Both are major culprits in treatment failure and poor prognosis for CRC. Method. A systematic review and meta-analysis of various research was done following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. This trial is registered with PROSPERO… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 140 publications
0
2
0
Order By: Relevance
“…In a meta-analysis of 88 studies, Afolabi et al detected the majority of KRAS mutations in codon 12 (78.2%) followed by codon 13 (21%). The rate of BRAF mutation was 5.6% [33]. While the Belgian study detected 91% of the mutations in codon 12 in KRAS (+) patients [10], this rate was only 29.3% in a study by Symvoulakis et al in the Greek population [34].…”
Section: Discussionmentioning
confidence: 85%
“…In a meta-analysis of 88 studies, Afolabi et al detected the majority of KRAS mutations in codon 12 (78.2%) followed by codon 13 (21%). The rate of BRAF mutation was 5.6% [33]. While the Belgian study detected 91% of the mutations in codon 12 in KRAS (+) patients [10], this rate was only 29.3% in a study by Symvoulakis et al in the Greek population [34].…”
Section: Discussionmentioning
confidence: 85%
“…In colorectal cancer KRAS (including Raf/Ras/MEK/ Erk), EGFR, c-Met, Apo2L, FAK, NF-κB are plausible molecule targets (Moser et al 2009;Therkildsen et al 2014;Alwers et al 2019;Henderson et al 2019;Reynolds et al 2019;Levin-Sparenberg et al 2020;Afolabi et al 2022). HSP90 inhibition of HIF-1α with STA-9090 (Cercek et al 2014), and inhibition of c-Met and FAK using AUY-922 appear to demonstrate a clinical activity and disease control (Subramaniam et al 2015).…”
Section: Discussionmentioning
confidence: 99%
“…Although CRC progression involves multi-gene aberration of several biomarkers, the identification and confirmation of prognostication factors and biomarkers can improve the management as an adjunct to the clinicohistopathology data of the patients [ 3 , 10 ]. How?…”
Section: Introductionmentioning
confidence: 99%